Fortress Biotech
Most recent annual filing: 2026-03-31
- ATX-04 clenbuterol trial start2026ATX-04 clenbuterol trial start, 2026, routine
- Cyprium dividend corporate update3Q 2026Cyprium dividend corporate update, 3Q 2026, routine
- Dotinurad Ph3 toplineLate 2026Dotinurad Ph3 topline, Late 2026, material
- Triplex Ph2 readoutEnd of 2026Triplex Ph2 readout, End of 2026, notable
- MB-109 Ph1 start4Q 2026MB-109 Ph1 start, 4Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
UNLOXCYT
cosibelimab-ipdlZYCUBO
copper histidinate injection · copper histidinate · CUTX-101anselamimab
CAEL-101 Protein Target: light chain fibrils
triplex
Protein Target: cytomegalovirus
- Undisclosed indication
AJ201
Small Molecule Target: Nrf1, Nrf2, androgen receptor
- Undisclosed indication
BAER-101
Small Molecule Target: GABAA α2/3
- Undisclosed indication
clenbuterol
ATX-04 Small Molecule Target: β2-adrenergic receptor
Amzeeq
Zilxi
dotinurad
Small Molecule Target: URAT1
MB-109
Biotech Distilled coverage (7)
- 2026-08-14 UPDATE: Fortress Biotech (FBIO) - The Three Lines I Was Watching All Printed 🔒 Paid
- 2026-08-13 UPDATE: Fortress Biotech (FBIO) - The Spoke Keeps Printing, The Hub Keeps Discounting 🔒 Paid
- 2026-07-28 UPDATE: Fortress Biotech (FBIO) - The Free Option Just Got Funded 🔒 Paid
- 2026-05-15 UPDATE: Fortress Biotech (FBIO) - The Parent Balance Sheet Finally Prints 🔒 Paid
- 2026-05-14 UPDATE: Fortress Biotech (FBIO) - Journey Hits Positive EBITDA, Emrosi Triples YoY 🔒 Paid
- 2026-04-27 UPDATE: Fortress Biotech (FBIO) - The PRV Cash Lands, The Covenants Vanish, The Stock Bleeds Anyway 🔒 Paid
- 2026-02-24 Fortress Biotech (FBIO): Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.